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Introduction 
Hepatoblastoma (HB) is a rare malignant embryonal tumour of the 
liver that occurs in young infants with a median age at diagnosis of 
18 months and its annual incidence is below 0.15 patients per 100,000 
population under 15 years of age [1]. HB accounts for 1% of new cancer 
diagnoses in childhood and is the most common childhood liver cancer 
[2].  HB etiology is still unknown, most cases are sporadic whereas 
several genetic syndromes are associated with approximately 15% of 
cases and a close association with developmental syndromes such as the 
Beckwith-Wiedemann Syndrome (BWS) and Familial Adenomatous 
Polyposis (FAP) has been widely described [3,4,5]. 
Several distinct histological subtypes of HB have been identified. 
This heterogeneous tumor spectrum reﬂects different patterns 
of embryonal liver development and maturation, indicating a 
developmental origin for HB and a huge variation in the clinical 
outcome [6]. Five biomarkers, β-catenin, E-cadherin, Cyclin D1, Ki-
67 and alpha-fetoprotein, have been widely described in HB onset 
and progression [6-11]. Among these markers, β-catenin is deeply 
involved in Wnt/β-catenin pathway playing a central-key role in hepatic 
development, regeneration, and tumorigenesis. Notably HB presents 
the highest rate (50–90%) of β-catenin mutations [12]. Nevertheless, 
Wnt and β-catenin expression are not always sufficient to characterize 
the differences between tumoral and non-tumoral in HB samples 
[13]. As an example, despite Adenomatous polyposis coli (APC) or 
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Abstract
Hepatoblastoma (HB) is the most common liver cancer in infants younger than 3 years. Its onset has been 
associated with other genetic syndromes and some genetic and biochemical markers has been identified recently in 
this neoplasia. Nevertheless the patients have a poor prognosis and the resection or transplantation remains the only 
effective therapeutic approach. The identification of non-invasive markers may represent an innovative approach 
and may contribute to a more accurate histological classification of this tumor. We previously demonstrated that 
some microRNAs are helpful in discriminating HB from hepatocellular carcinoma. In this study, we describe the 
involvement of the two forms of microRNA-483 (-3p and -5p) in a selected cohort of HB patients who underwent 
surgical resection or liver transplantation. Differently from other liver diseases we observed that the quantitative 
expression of the two forms did not significantly changed among patients. Furthermore, 3p/5p ratio was different 
between HB and non-HB samples, being positive in the latter and negative in HB samples. Influence of concomitant 
treatments in the expression of miR-483 (i.e. chemotherapy, and immunosuppressive drugs) was also evaluated 
and no changes were found in the follow-up. In conclusion the expression and function of miR-483-3p/5p in HB still 
remains unclear and further studies are needed to elucidate the possible mechanisms that regulate the different 
strand selection between the two forms of microRNA-483 in patients affected by HB. We deem that the analysis of 
microRNA-483 different forms could be useful for the molecular identification of HB patients and the discrimination 
with non-HB patient.
β-Catenin mutations are present in all colon cancer cells, WNT pathway 
is not always activated. Furthermore, high WNT activity and nuclear 
β-Catenin expression were often found to the tumor margin area, 
reflecting an intratumoral WNT signaling heterogeneity [14,15]. This 
phenomenon has been termed the “β-Catenin paradox” and led to the 
discovery that other specific modulators (i.e. hepatocyte growth factor 
and mitogen-activated protein kinase) may modulate WNT signaling 
activity with APC or β-Catenin mutations, thus contributing to a WNT 
mediated tumor progression [16-20]. 
HB is still burdened by a poor prognosis and invasive intervention, 
and the only effective therapeutic approaches are the liver resection 
or transplantation with a significant rate of unfavorable outcomes. 
The identification of HB molecular biomarkers, collectable from 
patients through blood or organic fluids, may represent a less invasive 
approach useful not only for the histological characterization but 
also for the comprehension of the biological pathways involved in 
HB tumorigenesis. This would lead to an increased knowledge on its 
pathogenesis and it might influence the overall survival rates [6]. 
MicroRNAs (miR) are small non-coding RNAs that influence the 
pathogenesis of human diseases, including cancers, by binding their 
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target messenger RNAs preventing the protein translation [21]. From 
the functional point of view they can either act as oncogenes or tumor 
suppressors. Large-scale approaches have been shown that several miR 
differentially expressed in liver tumors are involved in the progression 
of the disease [13, 22-26]. 
We previously demonstrated that five miRs (miR-214, miR-199a, 
miR-150, miR-125a, and miR-148a) are useful in discriminating HB 
from hepatocellular carcinoma (HCC), thus representing a new class of 
markers for the classification of pediatric liver tumors [13]. Preliminary 
data from gene expression profile in this work also highlighted the 
involvement of miR-483.
MiR-483 gene is located on genomic chromosome at 11p15.5 in the 
second intron of Insulin-like Growth Factor 2 (Igf2) and produces two 
mature different forms: miR-483–3p and miR-483–5p, differentially 
involved in liver pathologies [27,28-34]. MiR-483-5p and miR-483-3p 
were identified from a human embryonic liver. Reports have suggested 
that some intragenic miRNAs co-express and cooperate with their host 
genes, but that other miRNAs do not. Igf2 over-expression promotes 
proliferation and carcinogenesis during the progression from liver 
fibrosis to HCC. In addition, miR-483 is up-regulated in approximately 
half of human tumors including adrenocortical carcinoma and HCC, 
and its oncogenic targets (PUMA, CTNNB1, IGF1R) have been 
identified [35,36]. 
The biogenesis of miRs involves the stepwise cleavage of a long 
primary miR (pri-miR) transcript in a small hairpin-shaped RNA called 
pre-miRNA. About one third of miR genes are located in the introns 
of protein-coding genes; these are overwhelming found on the sense 
strand, implying a linkage of miR and host mRNA transcription. Once 
in the cytoplasm, the pre-miR hairpin is recognized and cleaved within 
its stems. This yields paired ~22 nt RNAs, known as the miR-5p/miR-3p 
duplex formed by two strands, one of which is degraded. Recent studies 
indicate that the dominant forms of a miRNA differs amongst tissues, 
times of development, and between species, suggesting the existence 
of other mechanisms for controlling the selection of mature miR [37].
In the present study we evaluated the content of the two different 
forms of miR-483 in a selected cohort of HB patients who underwent 
surgical resection or liver transplantation. By the analyses of the biopsies 
from surgical tissue samples we found that the relative concentration of 
the miR-483-5p was higher than the -3p one in HB patients. Conversely, 
in non-HB patients, the relative concentration of the -3p form was 
predominant. Furthermore, we demonstrated that the two forms were 
also detectable in serum samples, suggesting the potential use of miR-
483 as noninvasive biomarkers for HB. Finally and most importantly, 
by analyzing patients in the follow-up, we found the same pattern of 
expression of the two forms, leading to the hypothesis that, although 
the exact cause of liver cancer is still unknown, some genetic factors 
may contribute to miR483-5p expression independently by the healthy 
status of a patient after tumor treatment. 
Materials and Methods
Case selection 
A total of 14 unrelated confirmed cases of HB (Patient, Pt) 
were included in the study. They all received surgical treatment (3 
liver resection and 11 liver transplantation) at the General Surgery 
Department and Liver Transplant Center of the AOU Città della Salute 
e della Scienza di Torino, Italy. Written informed consent was obtained 
from parents of all patients for these studies.
Two patients deceased in the follow-up following transplantation, 
while one resected patient was lost to follow-up.
Seven tissue samples were obtained from surgical specimens 
immediately after tumor removal. Ten serum samples were collected 
from HB patients in the follow-up after surgical treatment (Table 1). 
In three cases (Pt1, Pt3, Pt7) we analyzed both tissue and serum. With 
regards Pt4 we included an RNA extracted from a non-neoplastic part 
of a liver explanted for HB (Ctr3).
In all cases, histopathological diagnosis of HB was obtained from 
specimens of percutaneous ultrasound-guided biopsy. Pre-operative 
staging was based on computed tomography imaging, according to 
PRETEXT criteria. All patients underwent neo-adjuvant chemotherapy, 
according to Société Internationale d’Oncologie Pédiatrique – Epithelial 
Liver Tumor Study Group (SIOPEL) protocols [9].
Non-HB samples (Control, Ctr) were also included in the study. 
As regard tissue analyses, we used two RNAs from normal individuals: 
Ctr1 sample was a pooled RNA from a fetal liver and Ctr2 was a pooled 
RNA from adult liver. Both Ctr1 and Ctr2 were commercially purchased 
by Clontech. 
Regarding serum samples, we included 14 non-HB individuals 
in the study. In particular, Ctr4 to Ctr13 had undergone liver 
transplantation for non-neoplastic diseases (Familial cholestasis, Biliary 
atresia, Sclerosing cholangitis, Vascular anomaly, Urea cycle disorder); 
Ctr14 to Ctr17 were healthy donors. Tacrolimus was administered 
to Ctr4 to Ctr13 controls as first line immunosuppressor (Table 1S – 
supplementary data). 
All data were collected from medical record. For each patient, 
histopathological diagnosis was confirmed from two different 
pathologists by revision of the liver biopsies. Written informed consent 
for biological studies was obtained also from all controls or their families. 
microRNA isolation from tissues 
Total RNA from HB tissues was isolated using TRIzol reagent 
(Invitrogen, Carlsbad,CA, USA) following the manufacturer’s 
instructions. Two commercial RNA extracted from a fetal (Ctr1) and 
adult liver (Ctr2) tissue were also used as control RNA in order to test 
our hypotheses. 
microRNA isolation from serum
The total RNA, including miRs, was extracted from serum using 
the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany). Two 
hundred microliters of serum were mixed with denaturing buffer in the 
volumes described in the manufacturer’s protocols. The homogenate 
was incubated at room temperature for 5 min. Subsequently, the 
manufacturer’s protocols were followed for RNA extraction. Total RNA 
was eluted into 14 μl of nuclease-free water. The RNA concentration was 
measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). 
TaqMan real-time PCR
To specifically evaluate mature miRs, TaqMan® MiRNA assay kits 
were purchased from Life Technologies® (Foster City, CA) to detect 
miR-483-3p and miR-483-5p. It is a two-step protocol requiring reverse 
transcription with a miR specific primer, followed by real-time PCR 
with TaqMan probes. 
Mature miR expression was assayed by TaqMan MicroRNA assay 
(Life Technologies®) specific for miR-483-3p and miR-483-5p. 
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RNA from tissue was normalized by using RNU6B as endogenous 
controls due to its highest abundance and least variability across 
normal tissues. RNA from serum was normalized with miR-16 due to 
its expression at high levels in serum and its relatively low variation 
across large numbers of samples. Ten nanograms of total RNA were 
reverse-transcribed using the specific looped primer and quantitative 
real-time reverse transcription PCR (qRT-PCR) was conducted using 
the standard TaqMan MicroRNA assay protocol. The 20 μL PCR 
included 1,33 μL of reverse transcription product, 1× TaqMan Universal 
PCR Master Mix, No AmpErase UNG, 0.2 μmol/L TaqMan probe, 1.5 
μmol/L forward primer, and 0.7 μmol/L reverse primer. The reaction 
was carried out in a 96-well PCR plate at 95°C for 10 min followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min. Each sample was analyzed 
in triplicate.
The levels of miR were measured using Ct (threshold cycle). The 
amount of target, normalized to an endogenous reference and relative 
to a calibrator, is given by 2−ΔΔCt (comparative Ct method; ABI user’s 
bulletin ‘Relative Quantitation of Gene Expression: ABI PRISM 7700 
Sequence Detection System: User Bulletin 2: Rev B). Real-time PCR 
was performed using the 7500 Fast Real-Time PCR System (Applied 
Biosystems). 
Statistical analysis
Each experiment was repeated at least three times independently. 
All results were expressed as mean (standard deviation), and p< 0.05 
was used for statistical significance. One-Way ANOVA analysis for 
independent samples was used to determine statistically significant 
differences.
S Serum
T  Tissue
OLT Orthotopic Liver Transplantation
CT Chemotherapy 
*  Age at SLR (Surgical Liver Resection) 
NA Not applicable
§ Commercial RNA (Clonetech)
† Dead patient
- Not available
° hepatic resection
Table 1. Clinical features of HB patients (Pt, N=14) and Controls (Ctr, N=17) enrolled in the study 
Sample Sample type Gender Age at OLT (mths) preCT state CT treatment
Days of
follow up Diagnosis
Pt1 T + S F 20 Pretext III, P1 SIOPEL IV 1240 Hepatoblatoma
Pt2† T M 23 Pretext III, P1 SIOPEL IV 2 Hepatoblatoma
Pt3 T + S F 31 Pretext IV,  V1 SIOPEL IV 1410 Hepatoblatoma
Pt4† T F 37 Pretext III SIOPEL III 150 Hepatoblatoma
Pt5° T M 15* Pretext II SIOPEL III 2160 Hepatoblatoma
Pt6° T M 143* Pretext II SIOPEL III lost Hepatoblatoma
Pt7 T + S F 8 Pretext III, P1 V2 SIOPEL IV 1021 Hepatoblatoma
Pt8° S M 17* Pretext II SIOPEL IV 345 Hepatoblatoma
Pt9 S F 34 Pretext IV SIOPEL III 2550 Hepatoblatoma
Pt10 S M 30 Pretext IV,  P1, V2 SIOPEL III 2023 Hepatoblatoma
Pt11 S M 14 Pretext IV SIOPEL IV 471 Hepatoblatoma
Pt12 S M 63 Pretext IV SIOPEL II 4747 Hepatoblatoma
Pt13 S F 32 Pretext IV SIOPEL IV 1266 Hepatoblatoma
Pt14 S M 8 Pretext III SIOPEL III 1873 Hepatoblatoma
Ctr1§ T M/F 20-38 weeks NA NA NA Normal pooled human fetal livers
Ctr2 § T M 288-768 NA NA NA Normal pooled livers
Ctr3† T F 37 Pretext III SIOPEL III 150 non-neoplastic part of a liver explanted for HB
Ctr4 S M 37 NA NA 559 Familial cholestasis
Ctr5 S M 8 NA NA 849 Biliary atresia
Ctr6 S M 192 NA NA 1415 Sclerosing cholangitis
Ctr7 S F 95 NA NA 3292 Vascular anomaly
Ctr8 S F 5 NA NA 3281 Biliary atresia
Ctr9 S F 73 NA NA 1273 Familial cholestasis
Ctr10 S F 96 NA NA 1101 Sclerosing cholangitis
Ctr11 S M 49 NA NA 842 Urea cycle disorder
Ctr12 S M 12 NA NA 6734 Biliary atresia
Ctr13 S F 13 NA NA 7307 Biliary atresia
Ctr14 S F 18 NA NA NA Healthy donors
Ctr15 S M 13 NA NA NA Healthy donors
Ctr16 S M 25 NA NA NA Healthy donors
Ctr17 S F 22 NA NA NA Healthy donors
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Results 
Patient characteristics
Clinical and histopathologic characteristics of patients and 
controls enrolled in our study are presented in Table 1 and in Table 1S 
(supplementary data).
All patients had a formal diagnosis of HB. The tumours were examined 
centrally (General Surgery Department and Liver Transplant Center of the 
AOU Città della Salute e della Scienza di Torino, Italy) and classified as 
wholly epithelial and well differentiated fetal (N=6), mixed epithelial and 
mesenchymal (N=3), mixed embryonal and fetal (N=5) (Table1S). 
PRETEXT staging was type III in 5 patients, type IV in 6 and type II in 
3. All patients underwent a SIOPEL-guided neo-adjuvant chemotherapic 
treatment (SIOPEL II, N = 1; SIOPEL III, N=6; SIOPEL IV, N=7). 
Surgery consisted in liver resection in 3 cases (Pt5, Pt6, Pt8) and 
liver transplantation in the other 11. Age at transplantation in HB 
patients ranged from 8 to 63 months (15 to 143 months for the 3 liver 
resections) and male to female ratio was 1.33:1.
After transplantation, 2 cases were diagnosed with acute rejection 
(Pt3 and Pt10), which was treated with steroids. Furthermore, one 
post-transplant lymphoproliferative disease was detected (Pt1) and 
treated with a reduction of Tacrolimus in association with Rituximab. 
Finally, one patient developed pneumonia (Pt11) and was treated with 
antibiotic therapy. Surgical complications involved bile ducts in two 
patients (Pt12 and Pt9): one was managed and treated with biliary 
reconstruction, the other was re-transplanted (Pt9). Bowel volvulus was 
diagnosed in Pt3 who underwent emergency surgery.
Postoperative chemotherapy was administered, according to 
SIOPEL protocols, to all patients and no recurrence was detected so far 
[9]. In the follow-up, patients received periodic physical examinations, 
laboratory investigations which included complete blood count, liver 
function tests, alpha-fetoprotein level, and ultrasonography. 
The mean follow up is now of 1,375 days. All children enrolled in 
the study are currently alive, except two (Pt2 and Pt4) who died due 
to complications after transplantation and HB recurrence, respectively. 
One resected patient was lost at follow-up (Pt6). Pt4 was a liver sample 
explanted for HB and matched with its non-neoplastic part (Ctr3).
miR-483-3p and miR-483-5p expression in tissues
We previously demonstrated that whole miR profiling identified 
differentially expressed miR that was commonly deregulated in HB 
patients [13]. It was found that 33 of 51 filtered miR were differentially 
expressed: 21 of them resulted to be up-regulated and 12 were down-
regulated. Among these miRs we also observed a large heterogeneity 
in miR-483 expression. When we analyzed the ratio of the two forms 
(-3p and -5p) we found that the -5p form was higher than the -3p in 
tumoral tissue compared to non tumoral ones. In order to validate this 
observation we performed quantitative real-time PCR on surgical HB 
tissue samples. For this purposes we used probes corresponding to 
miR-483-3p and miR-483-5p. 
Figure 1 shows miR-483-3p/5p ratio on a log scale. MiR-483-3p 
levels were higher than those observed for miR-483-5p in control Ctr1 
and Ctr2 RNAs. Conversely in Ctr 3 (non–neoplastic part of Pt4) and 
in HB patients (Pt1-Pt7), ratio was inversed. Collectively, the absolute 
expression of the two forms did not correspond to an increased level of 
the transcription of a predominant isoform. 
miR-483-3p and miR-483-5p expression in serum
To extend our observation, we performed quantitative real-time PCR 
on serum samples from patients in follow-up after liver transplantation or 
surgical resection. In particular we analyzed 10 HB serum samples versus 
14 controls. As observed in tissues, in all HB patients, -5p form levels were 
higher than -3p ones when compared to controls; vice versa, in control 
samples the -3p form was predominant (Figure 2).
In two controls (Ctr5, Ctr11) an inversion in the pattern of the 
ratios was observed. In order to explain this variation, we evaluated 
whether chemotherapy or adjunctive therapies could have influenced 
the results. Ctr 5 was affected by biliary atresia and had received 
basiliximab and Tacrolimus as induction of immunosuppression, while 
Ctr11 was affected by Urea cycle disorder and had been induced with 
basiliximab only. As shown in Table 1S also other controls were treated 
with the same immunosuppressive drugs and no effect on the overall 
results was observed. So far, we concluded that for both Ctr 5 and 
Ctr11 no correlation with molecular analyses was found neither with 
chemotherapy nor with immunosuppressive treatments. 
Figure 1: Mir-483-3p/5p ratio (log scale) in tissue samples. MiR-483-3p levels are higher than those observed for miR-483-5p in control Ctr1 and Ctr2 RNAs. Conversely 
in Ctr 3(non–neoplastic part of Pt4) and in HB patients (Pt1-Pt7) this ratio is inversed.
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Discussion
Hepatoblastoma is a rare malignant liver tumor affecting infants and 
many heterogeneous histological tumors subtypes have been described. 
Although the survival rates have improved dramatically in recent years, 
there still exists a subset of HB that does not respond to treatment [6]. 
There are currently no specific molecular biomarkers in use and several 
studies are aimed at evaluating new potential biomarkers useful in 
facilitating the early diagnosis. 
MiRs comprise a family of highly conserved small noncoding 
RNAs (-22 nt). As regulators of post-transcriptional gene expression, 
they play an essential role in a large number of physiological and 
pathological processes and a number of recent reports have confirmed 
their usefulness as biomarkers in cancer [38-42]. Furthermore, 
circulating RNAs in plasma and serum of cancer patients represents an 
emerging field for noninvasive diagnostic applications. In fact several 
studies largely focused on distinguishing cancer patients from control 
subjects using serum or plasma miRs as biomarkers [43,44].
Regarding liver diseases, numerous reports have demonstrated 
that alterations in the expression of intracellular and extracellular miR 
correlate with viral-related hepatitis, non-alcoholic steatohepatitis, liver 
fibrosis and HCC [45,46].
In particular, several miRs have been identified to be implicated 
in HB tumor onset and progression [22,26]. Among these, miR-483 
seems to play an important role in different types of human tumors 
such as colon, breast, and adult liver cancers, exhibiting different level 
of expression in about 30% of the cases [30,32,34]. 
We previously demonstrated that five miRs (miR-214, miR-199a, 
miR-150, miR-125a, and miR-148a) were helpful in discriminating 
HB from hepatocellular carcinoma (HCC), thus representing useful 
markers for the classification of pediatric liver tumors [13]. 
Data from gene expression profile in our work also highlighted 
an heterogeneity in the expression of miR-483, being some samples 
upregulated and some others not. MiR-483 gene is located on genomic 
chromosome at 11p 15.5 in the second intron of IGF2 and produces two 
mature forms (miR-483–5p, miR-483–3p). The functions of both forms 
have been sparsely studied to date and its relevance to carcinogenesis 
remains unclear. 
In the classic model of miR biogenesis, the duplex of mature 
miRNAs is produced by Dicer processing of the hairpin precursor. 
Then, a following strand selection step determines which mature 
miR will act as guide for the mature miR-mediated silencing complex 
(miRISC). The strand selection process is finely regulated and may vary 
among tissues and between normal and malignant cells.
Recent studies have been introduced innovative concepts and 
unraveled that both sister mature miR may be accumulated in some 
tissues and cell types. In this scenario, the strand selection might not be 
deterministic but tissue-specific, so that and a given strand could be the 
guide strand in a specific cell type and passenger in another one [47]. 
In this respect different biological contexts most likely share complex 
mechanisms of strand selection regulation, leading either to alternative 
expression of a single mature form or to concurrent expression of both 
mature sister miR [48].
MiR-483-3p has been found to be upregulated in 100% of Wilms’ 
tumors and in 33% of HCCs via IGF2 and beta catenin pathways [27]. 
IGF2 is frequently overexpressed in pediatric cancers. 
Recently, it has been shown that the different expression of miR-483 
contribute to the development of HCC from liver fibrosis, which was 
previously suggested to be a continuous process. These observations 
lead to the hypothesis that that different cell types should be evaluated 
individually in the development of liver fibrosis to HCC. All these data 
suggest that a more complex molecular mechanism creates is involved 
in these continuous changes [36]. 
The potential involvement of miR-483-3p in common human 
neoplasms has been widely studied in recent years. In particular, the 
overexpression of at least two functional elements from the IGF2 locus, 
the IGF2 protein and miR-483-3p, was considered to be essential in 
promoting tumorigenesis.
In our study, we evaluated the expression of both miR-483-3p and 
miR-483-5p in 14 unrelated confirmed cases of HB patients versus 
non-HB patients. The first evidence emerging from our analysis was 
that, on the contrary of what is described in other liver pathologies, the 
quantitative expression of the two forms did not significantly change 
along the two groups. 
Secondly, by the comparison of the ratio 3p/5p we observed an 
unbalance between HB and non-HB samples. In fact, while in the non-
HB group a positive ratio was observed, in the HB samples the ratio was 
in favor of the 5p form. 
Figure 2: Mir-483-3p/5p ratio (log scale) in serum samples. MiR-483-5p form levels are higher than -3p ones when compared to controls; viceversa, in control samples 
the miR-483-3p form is predominant. In Ctr5 and Ctr11 an inversion in the pattern of the ratios was observed. 
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Furthermore we also evaluated the potential influence of 
concomitant treatments in the expression of miR-483 and no 
correlations were found in patients undergoing to chemotherapy and/
or immunosuppressive regiments.
Finally in non-HB patients treated with standard therapy (i.e. 
immunosuppressive, antibiotics,etc.) for unrelated HB diseases, as well 
as healthy donors, no correlations with the treatment were found. 
These results suggest that, despite the stage of the tumor and/
or unrelated diseases or healthy status, miR-483-3p/5p ratio is not 
influenced by any treatment.
On the basis of our results we hypothesize that HB patients could 
present a specific molecular signature correlating miR-483-5p strand 
selection with HB; this hypothesis is supported by the preliminary 
observation in the only case available of matched HB vs non-HB sample 
from the same patient (Figure 1). 
Such preference may persist after tumor cure, thus representing 
a possible molecular marker to support classical diagnosis. As shown 
in Figure 1 and 2, HB samples from both tissue and serum are 
characterized by a positive ratio of miR-483-5p/3p, On the contrary the 
ratio was inverted in the majority of the non-HB samples, including 
healthy donors and patient undergoing to liver transplantation for 
pathologies different from HB. MiR-483-3p and -5p signature identified 
in HB patients may serve as a specific fingerprint for improving the 
accuracy in the diagnosis of this tumor. Even though at the moment 
it is not possible correlate the miR-483 expression with a specific HB 
histological subtype, we believe that the analysis of its two different 
forms may be useful in the molecular identification of HB patients 
and in distinguishing HB patients from non-HB ones (e.g. from HCC 
patients). We also suggest that the serum-based miR expression analysis 
could serve as novel noninvasive biomarkers in HB detection.
In conclusion, even if the involvement of miR in cancer onset and 
progression has been well described, a possible different strand selection 
between normal and cancer tissues has not been characterized yet. In 
this study the expression of the two forms of miRNA-483 was considered 
and particular attention was paid to the expression of the sister strands 
(-3p and -5p) in patients affected by HB. The two strands have different 
targets and are involved in different pathways. The alteration of the miR 
profile in the tumour microenvironment may be one of the strategies 
adopted by the tumor for its survival. For this reason we believe that 
further studies are necessary to elucidate the mechanisms that regulate 
this important biological process.
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